Recently, Gardin et al. [13] showed that integrating secondary AML-like gene mutations (ASXL1, SRSF2, STAG2, BCOR, U2AF1, EZH2, SF3B1, and ZRSR2) identifies a specific subset of high-risk patients and may thus improve the definition of high-risk older patients with AML [13]. This evidence concerns the gene SF3B1 and acute myeloid leukemia.